Figure 4.

Antiviral efficacy of UV-4B in lethal mouse models of influenza A (H3N2) and B virus infections. Female BALB/c mice (n = 10/group) were infected with ~1LD₉₀ of influenza virus via intranasal instillation. Mice were administered UV-4B diluted in sterile water. The dose levels are expressed as the active free base form, UV-4. Mice were orally treated with 50, 75, 100 or 150 mg/kg/dose of UV-4, vehicle or oseltamivir starting one hour before infection. Efficacy data are plotted as percent survival against days post virus exposure. Average weight changes/group are plotted versus days post virus exposure. (A,B) UV-4 efficacy following infection with influenza A/PA/10/2010 (H3N2) swine virus. In this study, UV-4 was administered for 7 days and oseltamivir was administered at 20 mg/kg/dose BID for 5 days. Mice were monitored for through 14 days post infection. (C,D) UV-4 efficacy following infection with influenza B/Sichuan/279/99. In this study, UV-4 was administered for 10 days and oseltamivir was administered at 10 mg/kg/dose TID for 5 days. Mice were monitored for through 21 days post infection. * p < 0.01, ** p < 0.001, *** p < 0.0001